



Research Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Synthesis, characterization, biological evaluation and docking studies of organo phosphorous pyrazole-5-one derivatives of 1,3,4-oxadiazole derivatives of sortase A staphylococcus inhibitors

¹N. Sandhya Rani, ¹G. V. Subbareddy*, ¹K. N. Jayaveera and ²L. K. Ravindranath

¹Department of Chemistry, Jawaharlal Nehru Technological University College of Engineering, Pulivendula, Andrapradesh, India

²Department of Chemistry, S. K. University, Anantapur, Andrapradesh, India

ABSTRACT

New novel derivatives of diethyl (1-(4-acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3, 4-oxadiazole-2-yl)methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1h-pyrazol-4-yl)(phenyl/4-methoxy/4-trifluoromethyl/4-nitrophenyl amino) methyl phosphate4(a-d) containing various heterocyclic substituent's were synthesized, characterized by elemental analysis, IR, ¹HNMR, ¹³CNMR, ³¹PNMR spectra and evaluated for in antimicrobial and antifungal activity. Molecular docking studies were performed to calculate docking scores and to propose the binding mode of 1,3,4-oxadiazole.

Keywords: pyrazole 5-one, 1,3,4-oxadiazole, Antimicrobial and Antifungal activity, docking studies of sortase A Staphylococcus inhibitors.

INTRODUCTION

The chemistry of phosphorous heterocyclic compounds containing nitrogen plays an important role in the development of new pharmaceutical materials with novel properties [1,2]. the organo phosphorous compounds and their derivatives were found to be the high light of study in lead compound discovery and biological screening and study of their various biological activities including its application in the field of agricultural, medicinal and industry [3,4]. Organophosphorous compounds occupied a unique position in biological activity such as anti bacterial [5], herbicides, insecticides, pesticides [6,7], antifungal agents [8], anti-HIV[9], anti-cancer [10], anti-viral and anti-inflammatory[11].

Heterocyclic compounds represents an important class of biologically active molecules specifically, those containing the pyrazolone nucleus have been shown to posses high biological activities such as tranquillizing, muscle relaxant, psychoanaleptic, anticonvulsant, antihypertensive, antidepressant activities. The derivatives of pyrazolone are important class of antipyretic and analgesic compounds [12-21].

Some substituted pyrazolones and their derivatives are used as antitumor [22], antibacterial [23], antifungal, antiviral, antiparasitic, anti-tubercular and insecticidal agents [23-28], some of these compounds have also anti-inflammatory [29], anti-diabetic [30], and anesthetic [31] properties.

A good deal of importance was given to 1,3,4-oxadiazoles and their derivatives in the field of organo phosphorous heterocyclic chemistry due to their unique biological applications [31]. In view of the above observations, we

synthesized pyrazole 5-one possessing 1,3,4-oxadiazole and screening for possible biological, pharmacological activities and docking sortase A staphylococcus inhibitory activity by silico methods.

EXPERIMENTAL SECTION

All the chemicals used in the present investigation were purchased from sigma-Aldrich chemicals company, Inc. USA. And used without further purification. TLC was performed on aluminum sheet of silica gel 60F₂₅₄, E-Merk, Germany using iodine as visualizing agent. Melting points were determined in open capillary tubes on Mel –temp apparatus and are uncorrected. Column chromatography was performed on silica gel with different solvent systems as eluents to afford the pure compounds. The IR Spectra were recorded as KBr pellets on Perkin –Elmer 1000units, instruments. All ¹H-NMR and ¹³C-NMR spectra were recorded on a Varian XL-300 Spectrometer operating at 400MHz for ¹H-NMR and 75 MHz for ¹³C-NMR. ³¹P-NMR spectra were recorded on a Varian XL-spectrometer operating at 161.89 MHz The compounds were dissolved in DMSO-d₆ and chemical shifts were referenced to TMS (H and C-NMR) and 85% H₃PO₄(³¹P-NMR). Mass spectral data was recorded on a Carlo Erba 1108 elemental analyser, Central drug Research Institute, Lucknow, India.

Docking method

Docking was carried out using GOLD (Genetic Optimization of Ligand Docking) software which is based on genetic algorithm (GA). This method allows as partial flexibility of protein and full flexibility of ligand. The compounds are docked to the active site of the Sortase A. The interaction of these compounds with the active site residues are thoroughly studied using molecular mechanics calculations. The parameters used for GA were population size (100), selection pressure (1.1), number of operations (10,000), number of island (1) and niche size (2). Operator parameters for crossover, mutation and migration were set to 100, 100 and 10 respectively. Default cutoff values of 3.0 Å (dH-X) for hydrogen bonds and 6.0 Å for vanderwaals were employed. During docking, the default algorithm speed was selected and the ligand binding site in the Sortase A was defined within a 10 Å radius with the centroid as CE atom of PHE136. The number of poses for each inhibitor was set 100, and early termination was allowed if the top three bound conformations of a ligand were within 1.5 Å RMSD. After docking, the individual binding poses of each ligand were observed and their interactions with the protein were studied. The best and most energetically favorable conformation of each ligand was selected.

RESULTS AND DISCUSSION

Typical procedure of the Synthesis of 2-(5-oxo-4- (phenyl/ 4-methoxy/ 4-nitro/ trifluoro methylphenylamino)methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1-phenylethylidene)acetohydrazide 2(a-d).

A mixture of (R) -2-(5-oxo-4-(phenylimino) methyl)-3-(trifluoromethyl)-4, 5-dihydro-1H-Pyrazole-yl)acetohydrazide(1a) and Acetophenone was refluxed in methanol containing a catalytic amount of glacial acetic acid for 4hours. After usual work up the hydrazone 2-(5-oxo-4-(phenylamino)methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1phenylethylidene) acetohydrazide 2(a) was obtained in 70% yield, m.p 139-142^oc.

The structure of these newly synthesized compounds 2(a-d) were based on the characterized by their elemental analysis and spectral data (¹H NMR, IR and Mass).

Typical procedure of the Synthesis of (1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-4-(phenyl/4-methoxy/4-nitro/4-trifluoromethylphenylamino)methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(a-d).


A mixture of hydrazones of 2-(5-oxo-4-(phenylamino) methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1phenylethylidene)acetohydrazide 2(a) and excess of acetic anhydride was refluxed for 2hours. The acetic anhydride was distilled off, and the reaction mass was poured on to crushed Ice. The solid thus obtained was filtered and recrystallized from aqueous DMF to give (1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-4-(phenylamino)methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(a) in yield 70% m.p 151-153^oc.

The procedure was adopted to synthesize (3b-d) by the reaction between 2(a-d) with acetic anhydride. The structure of these newly synthesized compounds 3(a-d) were characterized by their elemental analysis and spectral data (¹H-NMR and IR).

Typical procedure of the Synthesis of diethyl (1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(phenyl/4-methoxy/4-nitro/4-trifluoro methylphenylamino) methylphosphate4(a-d):

A mixture of (1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-4-(phenylamino)methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(a) and diethyl phosphate(0.50ml,0.004 mol)in an hydrous toluene(15ml) was added drop wise. Stirring was continued at room temperature for another 0.5 hour, after which the mixture was heated under reflux for 4-6 hours. The reaction was monitored by TLC on silica gel using petroleum ether-ethyl acetate(1:2v/v).After completion of the reaction, the solvent was removed by rota evaporator and the resulting residue was purified by column chromatography on silicagel(100-200 mesh)and ethyl acetate-hexane,(3:7 ratio) as an eluent afforded pure,diethyl(1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(phenyl amino)methylphosphate 4(a)was purified from aqueous dimethyl formamide. Yield 70%, mp 173-175°C.

The similar procedure was adapted to synthesis (4a-d) by the reaction between (3b-d) with diethyl phosphate. The structures of these newly synthesized compounds of (4a-d) were established by IR, ¹H-NMR, ¹³C-NMR, ¹³P-NMR, mass data and elemental analysis.



	1a	1b	1c	1d
COMPOUND	2a	2b	2c	2d
NUMBER	3a	3b	3c	3d
	4a	4b	4c	4d
R	H	OCH ₃	NO ₂	CF ₃

Physical, analytical and spectral data of compounds (2a-d)

Synthesis of 2-(5-oxo-4-(phenylamino) methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1-phenylethylidene) aceto hydrazide 2(a):

Yield (70%); m.p (139-142); IR (KBr, cm⁻¹) 3210(N-H), 3040(Ar-H), 1698(C=O), 1620(C=N); ¹HNMR(400MHz, DMSO-d₆): 2.45(s, 3H, -CH₃group), 3.32(d,1H,-CH of pyrazole ring), 4.20(s,2H,-N-CH₂-C=O) 7.50(d,1H,-CH=N), 6.98-7.52(m,10H,2(C₆H₅)groups), 8.61(s,1H,(O=C-NH));Anal.calcd(%) for C₂₁H₂₀F₃N₅O₂: C 58.74%,H 4.23% and N 16.31% . Found: C 58.34%,H 3.83% and N 16.01%.

Synthesis of 2-(5-oxo-4-(4-methoxyphenylamino) methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1-phenylethylidene) aceto hydrazide 2(b):

Yield(70%);m.p(121-122); IR(KBr,cm⁻¹)3218(N-H), 3040(Ar-H), 1692(C=O), 1621(C=N); ¹HNMR(400MHz, DMSO-d₆):2.45(s,3H,-CH₃group), 3.32(d,1H,-CH of pyrazole ring),3.83(s,3H,-O-CH₃),4.20(s,2H,-N-CH₂-C=O), 7.50 (d,1H,-CH=N),6.99-7.94(m,9H, C₆H₄&C₆H₅), 8.61(s,1H,(O=C-NH));Anal.calcd(%) for C₂₂H₂₂F₃N₅O₃: C 57.51%,H 4.39% and N 15.24% . Found: C 57.41%, H 4.09% and N 14.84%.

Synthesis of 2-(5-oxo-4-(4-nitrophenylamino) methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1-phenylethylidene) aceto hydrazide 2(c):

Yield (70%); m.p (138-140); IR (KBr,cm⁻¹) 3221(N-H),3042(Ar-H),1696(C=O), 1615(C=N); ¹HNMR(400MHz, DMSO-d₆):2.45(s,3H,-CH₃group),3.32(d,1H,-CH of pyrazole ring),4.20(s,2H,-N-CH₂-C=O)7.50(d,1H,-CH=N), 6.91-8.10(m, 9H, C₆H₄&C₆H₅),8.61(s,1H,(O=C-NH));Anal.calcd(%) for C₂₁H₁₉F₃N₆O₄: C 53.17%,H 3.61% and N 17.72% . Found: C 52.87%, H 3.61% and N 17.32%.

Synthesis of 2-(5-oxo-4-(4-trifluorophenylamino) methyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(1-phenylethylidene) aceto hydrazide 2(d):

Yield (70%); m.p (159-160); IR (KBr,cm⁻¹)3213(N-H),3040(Ar-H),1692(C=O), 1617(C=N); ¹HNMR(400MHz, DMSO-d₆): 2.45(s,3H,-CH₃group),3.32(d,1H,-CH of pyrazole ring),4.20(s,2H,-N-CH₂-C=O)7.50(d,1H,-CH=N), 7.26-7.94(m,9H,C₆H₄&C₆H₅)groups),8.61(s,1H,(O=C-NH));Anal.calcd(%) for C₂₂H₂₂F₃N₅O₃: C 57.51%,H 4.39% and N 15.24% . Found: C 57.41%, H 4.09% and N 14.84%.

Physical, analytical and spectral data of compounds (3a-d)**Synthesis of (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3,4-oxadiazole-2-yl)methylphenylamino)methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(a):**

Yield(70%);m.p(151-153);IR(KBr,cm⁻¹)3040(Ar-H),1698(C=O),1620(C=N);¹HNMR(400MHz,DMSO-d₆): 1.83(s, 3H, -CH₃ group attached to oxadiazole),2.04(s,3H,-CO-CH₃),3.30(d,1H,-CH of pyrazole ring), 4.20(s,2H,-N-CH₂-), 6.98-7.45(m,10H,2(C₆H₅)groups);Anal.calcd(%) for C₂₃H₂₂F₃N₅O₃: C 58.60%,H 4.28% and N 14.86% . Found: C 58.20%, H 3.88% and N 14.86%.

Synthesis of (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3,4-oxadiazole-2-yl)methyl (4-methoxyphenyl amino)methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(b):

Yield(70%);m.p(167-169);IR(KBr,cm⁻¹)3040(Ar-H),1692(C=O),1621(C=N);¹HNMR(400MHz, DMSO-d₆): 1.83(s, 3H,-CH₃ group attached to oxadiazole),2.04(s,3H,-CO-CH₃),3.30(d,1H,-CH of pyrazole ring), 4.20(s,2H,-N-CH₂-), 6.85-7.45(m,9H,Ar-H of C₆H₅&C₆H₄groups) ;Anal.calcd(%) for C₂₄H₂₄F₃N₅O₄: C 57.48%,H 4.42% and N 13.97% . Found: C 57.08%, H 4.02% and N 13.57%.

Synthesis of (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3,4-oxadiazole-2-yl)methyl (4-nitrophenyl amino) methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(c):

Yield(65%);m.p(187-189);IR(KBr,cm⁻¹)3042(Ar-H),1696(C=O),1615(C=N); ¹HNMR(400MHz, DMSO-d₆): 1.83(s, 3H, -CH₃ group attached to oxadiazole),2.04(s,3H,-CO-CH₃),3.30(d,1H,-CH of pyrazole ring),4.20(s,2H,-N-CH₂-),6.72-7.45(m,9H,Ar-HofC₆H₅&C₆H₄groups);.Anal.calcd(%) for C₂₃H₂₁F₃N₆O₅: C 53.49%,H 3.71% and N 16.27% . Found: C 53.19%, H 3.31% and N 15.19%.

Synthesis of (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3,4-oxadiazole-2-yl)methyl (4-trifluorophenyl amino) methyl-3-(trifluoromethyl)-1H-pyrazol-5(4H)-one3(d):

Yield(65%); m.p(165-167); IR(KBr,cm⁻¹)3040(Ar-H),1692(C=O),1617(C=N); ¹HNMR(400MHz, DMSO-d₆): 1.83(s,3H,-CH₃ group attached to oxadiazole),2.04(s,3H,-CO-CH₃),3.30(d,1H,-CH of pyrazole ring), 4.20(s,2H,-N-CH₂-), 6.53-7.45(m,9H,Ar-H of C₆H₅&C₆H₄groups);Anal.calcd(%) for C₂₄H₂₁F₆N₅O₃: C 53.44%,H 3.55% and N 12.98% . Found: C 53.14%, H 3.15% and N 12.58%.

Physical, analytical and spectral data of compounds (4a-d)**Synthesis of diethyl (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3, 4-oxadiazole-2-yl) methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(phenylamino)methylphosphate 4(a):**

Yield(70%); m.p(173-175);IR(KBr,cm⁻¹)3040(Ar-H),1698(C=O),1620(C=N),1245(P=O), 1053 (O-C),743(P-O); ¹HNMR (400 MHz, DMSO-d₆): 1.29 (t, 6H, -CH₃ groups),1.83(s,3H,-CH₃of oxadiazole ring), 2.05(s,3H,-CO-CH₃),2.7(d,1H,-CH of pyrazole ring),2.9(d,1H,-CH attached to pyrazole),4.0(s,1H,Ar-NH),4.10(q,4H,2(O-CH₂-

groups), 4.20(s, 2H, -N-CH₂-), 6.83-7.38(m, 10H, Ar-H, 2(C₆H₅) groups); ¹³CNMR 75MHz, DMSO-d₆ δppm): 115.6, 13.3, 176.6, 125.5, 57.5, 62.2, 16.3, 52.5, 158.2, 90.2, 27.9, 142.6, 126.9, 128.5, 128.7, 168.5, 23.7, 147.6, 113.5, 129.5, 120.8 and these signals are due to C₁, C₂, C₃, C₄, C₅, C₆&C₈, C₇&C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅ & C₁₉, C₁₆&C₁₈, C₁₇, C₂₀, C₂₁, C₂₂, C₂₃ & C₂₇, C₂₄ & C₂₆, and C₂₅ Carbon atoms; ³¹P-NMR (161.89MHz, DMSO-d₆): 17.5; Anal. calcd (%) for C₂₇H₃₁F₃N₅O₆P: C 53.20%, H 5.13% and N 11.49%. Found: C 52.80%, H 4.73% and N 11.19%.

Synthesis of diethyl (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3, 4-oxadiazole-2-yl) methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(4-methoxyphenylamino) methyl phosphate 4(b):

Yield(70%); m.p(139-141); IR(KBr, cm⁻¹) 3040(Ar-H), 1692(C=O), 1621(C=N), 1253(P=O), 1047 (O-C), 743(P-O); ¹HNMR (400 MHz, DMSO-d₆): 1.29(t, 6H, -CH₃ groups), 1.83(s, 3H, -CH₃ of oxadiazole ring), 2.05(s, 3H, -CO-CH₃), 2.7(d, 1H, -CH of pyrazole ring), 2.9(d, 1H, -CH attached to pyrazole), 3.83(s, 3H, -O-CH₃), 4.0(s, 1H, Ar-NH), 4.10(q, 4H, 2(O-CH₂- groups), 4.20(s, 2H, -N-CH₂-), 6.83-7.38(m, 9H, of C₆H₅ & C₆H₄ groups); ¹³CNMR 75MHz, DMSO-d₆ δppm): 115.6, 13.3, 176.6, 125.5, 57.5, 62.2, 16.3, 52.5, 158.2, 90.2, 27.9, 142.6, 126.9, 128.5, 128.7, 168.5, 23.7, 139.9, 115.8, 115.1, 151.7, 55.8 and these signals are due to C₁, C₂, C₃, C₄, C₅, C₆&C₈, C₇&C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅ & C₁₉, C₁₆&C₁₈, C₁₇, C₂₀, C₂₁, C₂₂, C₂₃ & C₂₇, C₂₄ & C₂₆, and C₂₅, C₂₈ Carbon atoms: Anal. calcd (%) for C₂₈H₃₃F₃N₅O₇P: C 52.58%, H 5.20% and N 10.95%. Found: C 52.18%, H 4.90% and N 10.55%.

Synthesis of diethyl (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1,3, 4-oxadiazole-2-yl) methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(4-nitrophenylamino) methyl phosphate 4(c):

Yield(70%); m.p(121-122); IR(KBr, cm⁻¹) 3042(Ar-H), 1696(C=O), 1615(C=N), 1248(P=O), 1038 (O-C), 749(P-O); ¹HNMR (400 MHz, DMSO-d₆): 1.29(t, 6H, -CH₃ groups), 1.83(s, 3H, -CH₃ of oxadiazole ring), 2.05(s, 3H, -CO-CH₃), 2.7(d, 1H, -CH of pyrazole ring), 2.9(d, 1H, -CH attached to pyrazole), 4.0(s, 1H, Ar-NH), 4.10(q, 4H, 2(O-CH₂- groups), 4.20(s, 2H, -N-CH₂-), 6.72-8.04(m, 9H, Ar-H of C₆H₅ & C₆H₄ groups); ¹³CNMR 75MHz, DMSO-d₆ δppm): 115.6, 13.3, 176.6, 125.5, 57.5, 62.2, 16.3, 52.5, 158.2, 90.2, 27.9, 142.6, 126.9, 128.5, 128.7, 168.5, 23.7, 153.7, 114.4, 127.5, 136.3 and these signals are due to C₁, C₂, C₃, C₄, C₅, C₆&C₈, C₇&C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅ & C₁₉, C₁₆&C₁₈, C₁₇, C₂₀, C₂₁, C₂₂, C₂₃ & C₂₇, C₂₄ & C₂₆, and C₂₅ Carbon atoms ³¹P-NMR (161.89MHz, DMSO-d₆): 20.9 Anal. calcd (%) for C₂₇H₃₀F₃N₆O₈P: C 49.55%, H 4.62% and N 12.84%. Found: C 49.25%, H 4.22% and N 12.54%.

Synthesis of diethyl (1-(4acetyl-5-methyl-5-phenyl-4, 5-dihydro-1, 3, 4-oxadiazole-2-yl) methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-yl)(4-trifluoromethylphenyl amino) methyl phosphate 4(d):

Yield(68%); m.p(151-153); IR(KBr, cm⁻¹) 3040(Ar-H), 1692(C=O), 1617(C=N), 1241(P=O), 1042 (O-C), 750(P-O); ¹HNMR (400 MHz, DMSO-d₆): 1.29(t, 6H, -CH₃ groups), 1.83(s, 3H, -CH₃ of oxadiazole ring), 2.05(s, 3H, -CO-CH₃), 2.7(d, 1H, -CH of pyrazole ring), 2.9(d, 1H, -CH attached to pyrazole), 4.0(s, 1H, Ar-NH), 4.10(q, 4H, 2(O-CH₂- groups), 4.20(s, 2H, -N-CH₂-), 6.53-7.40(m, 9H, Ar-H of C₆H₅ & C₆H₄ groups); ¹³CNMR 75MHz, DMSO-d₆ δppm): 115.6, 13.3, 176.6, 125.5, 57.5, 62.2, 16.3, 52.5, 158.2, 90.2, 27.9, 142.6, 126.9, 128.5, 128.7, 168.5, 23.7, 150.9, 113.8, 125.9, 124.9, 124.1 and these signals are due to C₁, C₂, C₃, C₄, C₅, C₆&C₈, C₇&C₉, C₁₀, C₁₁, C₁₂, C₁₃, C₁₄, C₁₅ & C₁₉, C₁₆&C₁₈, C₁₇, C₂₀, C₂₁, C₂₂, C₂₃ & C₂₇, C₂₄ & C₂₆, and C₂₅, C₂₈ Carbon atoms ³¹P-NMR (161.89MHz, DMSO-d₆): 19.6 Anal. calcd (%) for C₂₈H₃₀F₆N₅O₆P: C 49.64%, H 4.46% and N 10.34%. Found: C 49.44%, H 4.06% and N 10.04%.

Biological activity:

Antimicrobial activity of these newly synthesized compounds was performed according to disc diffusion method, as recommended by the national committee of clinical laboratory. The synthesized compounds were used at the concentration of 250 µg/ml DMF as a solvent.

Antimicrobial activity:

Antibacterial activity

Antibacterial activity Organo phosphorus pyrazole 1,3,4-oxadiazoles (**4a-d**) reported in the exhibit moderate antibacterial activity against the *Staphylococcus aureus* NCCS 2079, *Bacillus Cerus* NCCS 2106, *Escherichia coli* NCCS 2065 and *Pseudomonas aeruginosa* NCCS 2200 at the concentration of 250 µg/disc. In this series structures consisting of **4c**, have shown increased effect on their antibacterial activity. The decreasing Oder of antibacterial activity of (**4a-d**) is as follows “**4c**>**4d**>**4b**>**4a**”.

Table 1: Antibacterial activity of newly synthesized compounds 4a-d

Comp no	R	Zone of inhibition (mm)			
		<i>Staphylococcus aureus</i> NCCS2079 250($\mu\text{g/ml}$)	<i>Bacillus cereus</i> NCCS2106 250($\mu\text{g/ml}$)	<i>Escherichia coli</i> NCCS2065 250($\mu\text{g/ml}$)	<i>Pseudomonas aeruginosa</i> NCCS2200 250($\mu\text{g/ml}$)
4a	H	18	13	15	16
4b	OCH ₃	19	14	16	17
4c	NO ₂	22	18	20	21
4d	CF ₃	20	16	18	19
Amoxicilline		27	24	22	25

Antifungal activity

Antifungal activity Organo phosphorus pyrazole 1,3,4-oxadiazoles (**4a-d**) reported in the exhibited moderate antifungal activity against the *Aspergillus niger* NCCS1196 and *Candida albicans* NCCS 3471 at the concentration of 250 $\mu\text{g}/\text{disc}$ In this series structures consisting of **4c** and have shown increased effect on their antifungal activity. The decreasing Order of antifungal activity of (**4a-d**) is as follows “**4c>4d>4a>4b**”.

Table 2: Antifungal activity of newly synthesized compounds (4a-d)

Com no	R	Zone of inhibition (mm)	
		<i>Aspergillus niger</i> NCCS1196 250($\mu\text{g/ml}$)	<i>Canadidaalbicans</i> NCCS 3471 250($\mu\text{g/ml}$)
4a	-H	13	12
4b	-OCH ₃	11	9
4c	-NO ₂	18	16
4d	-CF ₃	15	13
Ketoconazole		22	25

Docking studies of Organo Phosphorus Pyrazole5-one 1,3,4-oxadiazole (4a-d)

Synthesis and characterization of (1-(4acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazole-2-yl)methyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1h-pyrazol-4-yl)(Phenyl/4-methoxy/4-trifluoro/4-nitrophenylamino)methyl phosphate 4(a-d),

Table.3 Docking results of 4(a-d) on sortase A staphylococcus


Com no	R	Fitness	S(hb-ext)	S(vdw-ext)	S(hb-int)	S(int)
4a	H	19.02	1.00	29.08	0.00	-21.96
4b	-OCH ₃	24.84	1.96	30.77	0.00	-19.43
4c	-NO ₂	37.45	0.55	37.77	0.00	-15.02
4d	-CF ₃	28.27	0.18	32.20	0.00	-16.18


The docking studies of 4(a-d) were carried out on sortase A staphylococcus (PDB ID: 1T2P). The docking ligands were found to have some interactions between an oxygen atom of the ligands and sortase A staphylococcus protein. Moreover, these docked conformations formed hydrogen bond interactions with the active site of the protein. Bind pocket, common hydrogen bonding interactions were for formed between all the docked ligands and TYR89,CYS77,GLY82PDB, MET84, GLN364PDB, VAL80PDB.The order of protein-ligand hydrogen bond score is 4b>4a>4c>4d.

Besides hydrogen bonding interaction between ligand-protein, the vanderwalls interactions between ligand-protein were also noticed. The order of protein-ligand vanderwaals score of interaction with the protein. However the ligand fails to exhibit intramolecular hydrogen bonding with the ligand. The ligands exhibit minimum intramolecular strain. Finally, all the ligands exhibit moderate to good antimicrobial activity with sortase A staphylococcus protein. The order of gold score fitness value of the ligands is 4c>4d>4b>4a. According to gold score fitness value ligand 4c exhibits high binding activity with the protein and ligand 4c showed leads binding activity with the protein

Table 4: Hydrogen bonding interactions of compounds (4a-d) with sortase A staphylococcus

COMP NO	R	Number of hydrogen bonds	Atom		Bond Length (Å ^b)	Fitness
			protein	atom		
4a	-H	3	VAL80PDB	8(P=O)	2.666	19.02
			CYS77	5(C=O)	2.663	
			MET84	22(C-O)	2.608	
4b	-OCH ₃	3	TYR67	8(P=O)	2.413	24.84
			GLN364PDB	5(C=O)	2.148	
			MET84	22(C-O)	1.807	
4c	-NO ₂	2	GLN364PDB	8(P=O)	2.446	37.45
			MET84	5(C=O)	1.954	
4d	-CF ₃	1	MET84	8(P=O)	1.964	28.27





Comparative Gold score fitness values for compounds 4(a-d)

CONCLUSION

The newly synthesized compounds Organo phosphorous pyrazole 5-one containing 1,3,4-Oxadiazole 4(a-d) were found to be active in the study of anti-bacterial and anti-fungal activity. It can be concluded that this class of compounds certainly holds great promise to discover novel classes of antimicrobial agents.

Acknowledgements

The authors are grateful to Prof. L. K. Ravindranath professor in department of chemistry, S. K. University, Anantapur for providing necessary facilities for this work. They are also thanks to IICT Hyderabad and CDRI Lucknow for spectral and analytical data.

REFERENCES

- [1] ZiyaErdemKoc ; *Journal of Hazardous Materials.*, **2010**, 183, 251–255.
- [2] OzdenOzelGuuven et al; *Bioorganic & Medicinal Chemistry Letters.*, **2007**, 17, 2233-2236.
- [3] Gummadi et al.; *Der Pharma Chemica.*, 2(3), **2010**, 196-204.
- [4] MalleshappaNoolvi et al; *Arab. J.Chem.***2011**.
- [5] K.F. Ansari et al; *European J. Med.Chem.***2009**, 44, 4028–4033.
- [6] A.K.Tiwari et al; *Indian Journal of Chemistry.*,**2006**, 45-B, 489-493.
- [7] A.Anton Smith, K.Seiyadu Ibrahim, S.Parimalakrishnan, A.KottaiMuthu,P.Muthumani; *j. ofapplied chem.*,**2008** 1(4), 7-12.
- [8] Mukesh C. Sharma, Dharm V. Kohli, SmitaSharma;*International. J. Drug Del.*,**2010** 2, 265-277.
- [9] Mishra et al; *J. of Pharmacy Research.*, **2010**,3(2), 371-37.
- [10] Yusuf Ozkay et al; *Eur. J. Med. Chem.*, **2010**,45, 3293-3297.
- [11] Swastika Ganguly, AvinashPatil, and Sanjay Surana; *RasayanJ. Chem.*, **2008**, 1(3), 447-460.
- [12] Sartori.G, Maggi.R; *Science Synthesis.***2005**, 18, 665.
- [13] J.G. Atkinson, Y.Guindon, C.K Lau, US Patent, **1990**,4, 351.
- [14] KhiangteVanladinpuia.;Ghanashyam Bez* *Tetrahedron Letters* 52 (**2011**) 3759-3764.
- [15] IlkayYildiz-Oren.; Ismail Yalcin, Esin Aki-Sener*, ;Nejat Ucarturk; *European Journal ofMedicinal Chemistry***2004**,39 ,291-298.
- [16] NobbaVenkata Siva , Kumar , Sanjay DashrathViadya , Ramanatham Vinod Kumar , Shekhar Bhaskar Bhiruda ,RamchandraBhimrao mane ; *European Journal of Medicinal Chemistry***2006**, 41,599-604.
- [17] 1K Rubtsova and R D Zhilina, *ZhurPriklad Khim*,1956, 32, 604.
- (b) AV kirsanov and ES Levchenko, *J Genchem, USSR*, 26, 1977, 2555.
- [18](a)CD Reddy ; RSN Reddy ; CN Raju ; M Elmasri ; KD Berlin and S Subramanian ;*MagnResonChem* , **1991**, 29,1140,
- (b)CDReddy , D Berlin , RSN Reddy , CN Raju , M ElmasriandS Subramanian *phosphorus , Sulfurand Silicon* , **1993**, 81, 61.
- [19] L W Daash and SC Smith, *Anal Chem*, **1956**.23, 853, 1661,
- [20] DEC Corbridge, *J ApplChem*,**1956**. 6, 456,

- [21] LC Thomas and RA Chittenden, *ChemInd(London)* **1961**, 1913,.
[22] F W Bennet, H J Emeleus and RN Haszeldine, *J Chemsoc*, **1954**. 3598,
[23] L J Bellamy and LJ Beecher , *J Chemsoc* , **1953**. 475,1951;1701,1951:728,
[24] H J Emeleus, R N Haszeldine and R C Paul, *J Chemsoc*, **1955**.563,
[25] RM Silverstein, GC Bassler and TC Morrill, *Spectrometric Identification of Organic Compounds*, John Wiley and Sons, New York, **1981**.361
[26] NB Colthup, N H Daly and S E Wiberly, *Introduction to Infrared and Raman Spectroscopy*, Academic Press, New York, **1964**, 305,
[27] JR Van Wazer , CF Calis , JN Shoolery and RC Jones *J Am ChemSoc*, **1956**. , 78,5715.
[28] N Muller, Pc Lauter bur J Golden son, *J Am ChemSoc*, , **1956**, 78, 3557,